Strategic Partnership Between 365mc and Raziel Therapeutics Boosts RZL-012 Development in Korea
Strategic Collaboration to Advance RZL-012 Development
In a significant development in the field of aesthetic medicine, 365mc, a prominent medical institution in South Korea known for its innovative fat reduction treatments, has announced a strategic collaboration with Raziel Therapeutics, a global biopharmaceutical firm currently engaged in clinical development. This partnership aims to expedite the clinical and commercial advancement of RZL-012, an injectable treatment designed for focal fat reduction. The drug is now set to progress towards Phase 3 trials, a critical step in its development.
Background on 365mc and Raziel Therapeutics
365mc is recognized as South Korea's leading healthcare network focusing on fat management, boasting a patient-centered philosophy and an integrated approach to obesity treatment. The institution offers a comprehensive range of services, including surgical procedures, dietary advice, and behavioral therapy. Operating 21 branches across the nation, 365mc has not only established itself as a national leader but is also rapidly expanding internationally with successful ventures in markets like Indonesia, Thailand, and Vietnam, and a recent foray into the United States.
On the other hand, Raziel Therapeutics is at the forefront of innovative treatments, particularly focusing on the non-invasive reduction of localized fat. The company's lead product, RZL-012, is a new chemical entity tailored to selectively disrupt adipocyte membranes. This innovative approach results in significant localized fat reduction, making it applicable for aesthetic issues like the reduction of submental fat, commonly referred to as a